Succesfull treatment of dogs with cancer
Continious success for Attana's customer Prof. Ali Salanti and co-workers at University of Copenhagen. They have successfully treated dogs with cancer. The treatment is based on discoveries enabled by Attana.
An article in Horizon Magazine , which focus on leading European research, describe the successfull treatment of 15 dogs with cancer. The treatment is based on a therapeutic vaccine developed by the team of Prof. Salantis and enabled by findings using Attana's cell-based technology.
"We will start with a cancer vaccine and then … develop the malaria vaccine."
Professor Ali Salanti, University of Copenhagen, Denmark
For more information, please contact:
Teodor Aastrup, CEO Attana AB
tel: + 46 8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share prices, but is of general interest for the shareholders and hence should be communicated.
Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact email@example.com.